查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887184

转移性去势抵抗性前列腺癌 (mCRPC) 治疗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测 (2024-2032)

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 278 Pages | 商品交期: 请询问到货日

价格

转移性去势抵抗性前列腺癌 (mCRPC) 治疗市场成长驱动因子

由于晚期前列腺癌发生率的上升以及製药公司在标靶治疗和荷尔蒙疗法方面不断创新，全球转移性去势抵抗性前列腺癌 (mCRPC) 治疗市场正经历显着扩张。根据 2024 年的估值，该市场规模预计将达到 164.6 亿美元，这反映出越来越多的患者在对标准荷尔蒙疗法产生抗药性后需要更先进的治疗方案。 预计到2025年，市场规模将飙升至210.4亿美元，并在2032年进一步扩大至871.9亿美元，2025年至2032年的复合年增长率将达到22.5%。

北美地区在2024年占了53.77%的市场占有率，继续保持领先区域市场的地位，这得益于其先进的肿瘤医疗保健体系、强有力的报销政策以及对新一代疗法的快速应用。

晚期摄护腺癌日益严重的全球负担

转移性去势抵抗性前列腺癌（mCRPC）是前列腺癌中最晚期且最危及生命的类型，其特征是癌细胞转移至骨骼、肝臟和淋巴结，并且对雄性激素剥夺疗法（ADT）具有抗药性。前列腺癌发生率的不断上升持续推动着对新治疗方案的需求。 根据世界癌症研究基金会的数据，2022年全球将新增1,467,854例癌症病例，凸显了全球对有效肿瘤治疗日益增长的需求。

辉瑞、强生、安斯泰来、艾伯维和阿斯特捷利康等大型製药公司的存在进一步推动了市场的上升趋势。所有这些公司都拥有强大的研发管线，开展合作，并已获得创新型转移性去势抵抗性前列腺癌（mCRPC）治疗药物的监管批准。

市场驱动因素：创新与不断扩大的治疗管线

推动市场成长的关键因素之一是药物研发活动的激增，尤其是在下一代雄性激素受体抑制剂、PARP抑制剂、GnRH激动剂和放射治疗药物方面。 各公司正在加大对联合疗法的投资，旨在提高出现雄性激素剥夺疗法（ADT）抗药性患者的存活率。

一个值得注意的例子是默克公司和Orion Pharmaceuticals, Inc.于7月签署的合作协议。该协议专注于开发opebesostat（MK-5684/ODM-208），这是一种CYP11A1抑制剂，目前正在开发用于治疗转移性去势抵抗性前列腺癌（mCRPC）。这些进展凸显了人们对标靶、个人化癌症治疗日益增长的关注。

市场限制因素：治疗抗药性与副作用

儘管取得了令人鼓舞的进展，但mCRPC的治疗仍面临着重大挑战。荷尔蒙疗法抗药性仍然是临床应用的主要限制因素。癌细胞会随着时间的推移而适应，发生雄性激素受体突变，降低治疗效果。加州大学洛杉矶分校Jonsson综合癌症中心2023年的一项研究表明，肿瘤会随着时间的推移失去其 "管腔" 特性，使其对荷尔蒙疗法的反应降低，并使治疗方案更加复杂。

此外，mCRPC 治疗药物如 ZYTIGA（一种二异质性药物）、恩扎卢胺和阿比特龙均伴随副作用，包括高血压、肌肉疼痛、水肿和心律失常，这些副作用可能会影响患者的长期依从性。

机会：诊断性放射治疗与精准医疗

诊断性放射治疗的出现为 mCRPC 的治疗创造了新的可能性。这些方法将诊断成像与标靶放射性药物治疗相结合，在提高疗效的同时降低了毒性。 2023 年，Clarity Pharmaceuticals 推进了评估 64Cu/67Cu-SAR-bisPSMA 的 I/IIa 期 SECuRE 试验，进一步推动了 mCRPC 治疗策略朝向个人化、生物标记驱动型策略的转变。

按细分市场分析

2024年，雄性激素受体抑制剂因其在抑制睪固酮驱动的癌症生长方面发挥的关键作用，占了市场主导地位。

就给药途径而言，口服药物占了最大占有率，这主要得益于患者用药的便利性以及瑞卢戈利等新型口服製剂的上市。

荷尔蒙疗法仍然是最广泛使用的治疗类别，这得益于雄性激素剥夺疗法（ADT）在早期和晚期前列腺癌中的广泛应用。

区域展望

  • 预计到2024年，北美市场规模将达到88.5亿美元，主要得益于高诊断率、积极的临床研究活动以及新药的早期应用。
  • 欧洲仍将是第二大市场，这得益于Movember等提高公众意识的活动以及先进诊断工具的发布。
  • 预计到2032年，亚太地区将经历最快的成长，这主要得益于中国、日本、澳洲和印度的癌症发生率上升，以及肿瘤研究投入的增加。
  • 预计拉丁美洲和中东及非洲地区将保持稳定成长，这得益于癌症治疗基础设施的改善和患者获得先进疗法的机会扩大。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 2024年主要国家及地区摄护腺癌盛行率
  • 主要公司产品线分析
  • 替代疗法概述
  • 市场主要新创企业
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情的影响市场

第五章 全球转移性去势抗性前列腺癌 (mCRPC) 治疗市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 按药物类别划分
    • 雄性激素受体抑制剂
    • 微管抑制剂
    • 促性腺激素释放激素 (GnRH) 激动剂
    • 促性腺激素释放激素 (GnRH) 受体拮抗剂
    • 其他
  • 市场分析、洞察与预测 - 按给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测 - 按疗法划分
    • 化疗
    • 荷尔蒙疗法治疗
    • 标靶治疗
    • 免疫疗法
  • 市场分析、洞察与预测 - 按销售管道划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美转移性去势抗性前列腺癌 (mCRPC) 治疗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲转移性前列腺癌去势抗性前列腺癌 (mCRPC) 治疗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区转移性去势抗性前列腺癌 (mCRPC) 治疗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲转移性去势抗性前列腺癌 (mCRPC) 治疗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲转移性去势抵抗性前列腺癌 (mCRPC) 治疗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析 (2024)
  • 公司公司简介
    • 安斯泰来药厂
    • 辉瑞公司
    • 强生服务股份有限公司
    • 赛诺菲
    • 费林製药股份有限公司
    • 住友製药株式会社（Myovant Sciences GmbH）
    • 艾伯维公司
    • 阿斯特捷利康
    • 托玛公司
    • Dendreon Pharmaceuticals LLC
    • 拜耳股份公司
Product Code: FBI112690

Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market

The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is undergoing significant expansion as the prevalence of advanced prostate cancer rises and pharmaceutical companies accelerate innovation in targeted and hormonal therapies. According to the 2024 assessment, the market size reached USD 16.46 billion in 2024, underscoring the growing patient pool requiring advanced treatments after resistance to standard hormone therapy. The market is projected to increase sharply to USD 21.04 billion in 2025 and further surge to USD 87.19 billion by 2032, exhibiting a robust CAGR of 22.5% during 2025-2032.

With 53.77% share in 2024, North America remained the dominant regional market, supported by advanced oncology care systems, strong reimbursement policies, and rapid introduction of next-generation therapies.

Rising Global Burden of Aggressive Prostate Cancer

mCRPC represents the most advanced and life-threatening form of prostate cancer, characterized by metastasis to organs such as the bones, liver, and lymph nodes, along with resistance to androgen deprivation therapy (ADT). The escalating prevalence of prostate cancer continues to push demand for new therapeutic options. As per the World Cancer Research Fund, 1,467,854 new cancer cases were recorded in 2022, highlighting the increasing need for effective oncological treatments worldwide.

The market's upward trajectory is further fueled by the presence of leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Astellas Pharma, AbbVie, and AstraZeneca, all of which maintain strong pipelines, undertake collaborations, and secure regulatory approvals for innovative mCRPC therapies.

Market Drivers: Innovation and Expanding Treatment Pipelines

One of the principal forces driving market growth is the surge in drug development activities, especially next-generation androgen receptor inhibitors, PARP inhibitors, GnRH agonists, and radiotherapeutics. Companies are increasingly investing in combination therapies aimed at improving survival outcomes in patients who develop ADT resistance.

A notable example is the July partnership between Merck & Co., Inc. and Orion Corporation, focused on developing opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor for mCRPC. Such advancements highlight the increasing emphasis on targeted, personalized oncology.

Market Restraints: Treatment Resistance and Adverse Effects

Despite promising developments, mCRPC therapeutics face critical challenges. Hormonal therapy resistance remains a major limiting factor in clinical adoption. Cancer cells adapt over time, mutating androgen receptors and reducing treatment effectiveness. Research from the UCLA Jonsson Comprehensive Cancer Center in 2023 highlighted that tumors become less "luminal" over time, reducing responsiveness to hormone therapy and complicating treatment planning.

Additionally, mCRPC drugs-including ZYTIGA, enzalutamide, and abiraterone-are associated with side effects such as hypertension, muscle discomfort, edema, and arrhythmia, which may impede long-term adherence.

Opportunities: Radiotheranostics and Precision Medicine

The emergence of radiotheranostics is creating new opportunities in the mCRPC landscape. These approaches combine diagnostic imaging with targeted radiopharmaceutical therapy, enhancing efficacy and reducing toxicity. In 2023, Clarity Pharmaceuticals advanced its Phase I/IIa SECuRE trial evaluating 64Cu/67Cu-SAR-bisPSMA, reinforcing the shift toward personalized, biomarker-driven mCRPC treatment strategies.

Segmental Insights

Androgen receptor inhibitors dominated the market in 2024 due to their pivotal role in blocking testosterone-driven cancer growth.

On the route-of-administration front, oral drugs held the largest share, driven by patient convenience and the launch of new oral formulations such as relugolix.

Hormonal therapy remained the most widely used treatment class, supported by robust adoption of ADT in early and advanced prostate cancer stages.

Regional Outlook

  • North America reached USD 8.85 billion in 2024, benefiting from high diagnosis rates, strong clinical research activity, and early access to new drug launches.
  • Europe remains the second-largest market, bolstered by awareness campaigns such as Movember and the release of advanced diagnostic tools.
  • Asia Pacific is projected to be the fastest-growing region through 2032, fueled by rising prevalence in China, Japan, Australia, and India, along with increased investments in oncology research.
  • Latin America and Middle East & Africa are poised for steady growth due to improving cancer care infrastructure and growing patient access to advanced therapeutics.

Competitive Landscape

Key players include Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., AstraZeneca, Bayer AG, Tolmar Inc., Dendreon Pharmaceuticals LLC, and others. Major industry developments include FDA approvals for new PARP inhibitor combinations and radioligand therapies such as Pluvicto.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 12: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 13: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 14: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 15: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 17: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 18: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 19: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 20: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 22: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 24: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 25: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 27: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 28: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 29: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 30: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024 & 2032
  • Figure 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2024 & 2032
  • Figure 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 11: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 12: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 13: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country, 2024
  • Figure 17: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 18: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 19: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 20: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 21: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 22: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 23: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 28: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 29: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 30: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 31: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 32: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 33: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion),by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 38: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 39: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 40: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 41: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 42: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 43: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 48: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 49: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 50: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 51: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 52: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 53: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 57: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Share (%), By Company, 2024